Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA) held in October 2023.
27.11.2023 - Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trialPlanned clinical trial expected to be a . Seite 1
Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.
/PRNewswire/ Hope in Focus, a nonprofit dedicated to finding treatments and cures for blindness caused by rare inherited retinal diseases, presents its 2023.
Thyroid Eye Disease: Addressing the Need for Early Intervention and Comanagement healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.